1. Medtech Insight
  2. >>Geography
  3. >>Europe

Pulmonary Device Companies Take It To The Streets - In Europe

For the past decade, venture capitalists have invested in companies that are developing new technologies to treat late-stage chronic obstructive pulmonary disorders.Despite hundreds of millions in venture capital dollars, the companies have made little progress in bringing these products to market in the US. But this band of start-ups is taking the fight to the streets - of Europe.

For the past decade, venture capitalists have invested in companies that are developing new technologies to treat late-stage chronic obstructive pulmonary disorders such as emphysema, hoping to create a new line of devices to aid patients who can't draw enough oxygen from a single breath. ( See "Emphysema: Elusive Target for Device Companies," IN VIVO , December 2008 Also see "Emphysema: Elusive Target for Device Companies" - In Vivo, 1 December, 2008..) Despite hundreds of millions in venture capital dollars, the companies have made little progress in bringing these products to market in the US.

But this band of start-ups is taking the fight to the streets – of Europe. The Food and Drug Administration hasn't given any chronic obstructive pulmonary disorder-oriented device broad access...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

More from Geography

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.